Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns positive

Q1 FY2026 accounts receivables was $854K, compared with -$893K a year earlier. Trailing-twelve-month accounts receivables was $1.5M.

Context

  • Accounts receivables amounted to 8.7% of revenue in FY2025, down 11.8 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $854K or moves back toward the trailing-twelve-month quarterly average of $376K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$854K+317.3% QoQ
Last fiscal yearDec 2025
-$243K-103.0% YoY
LTMMar 2026
$1.5M-42.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+195.6%——
1 year-103.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(243K) USD
Year-over-year change
-103.0%

Accounts Receivables vs competitors

How RNAC compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -42.4% is the 5th highest of 7, against a peer median of +135.7%.
  • Accounts receivables amounts to 84.7% of revenue for RNAC, versus a peer median of 5.3%.
RNAC Competitors
Accounts Receivables for RNAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDWDMediWound Ltd.LTM Mar 2026$3.64M USD+1144.1%—25.1%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$2.71M USD-76.9%+101.6%5.3%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$1.5M USD-42.4%—84.7%
IVAInventiva S.A.FY2025€816.45K EUR-70.9%-40.3%18.2%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$405.95K USD+181.5%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$5K USD+171.4%—0.0%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$0 USD———
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$0 USD———
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
Peer median (excluding RNAC) —+135.7%+30.6%5.3%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Depreciation & Amortization1.25M1.29M843K1.15M2.96M
Deferred Income Tax2.4M(21.4M)(19M)287K(9.19M)
Stock-Based Compensation7.72M11.19M22.52M6.58M10.52M
Change in Working Capital(48.19M)(60.38M)4.97M(5.79M)(8.06M)
Accounts Receivables(2.69M)3.32M907K7.98M(243K)
Inventory211K920K000
Accounts Payables(219K)92K2.83M(2.93M)1.07M
Other Working Capital(45.5M)(64.71M)1.23M(10.84M)(8.89M)
Other Non-Cash Items2.13M2.29M159.21M51.52M60.14M
Operating Cash Flow(60.38M)(31.63M)(51.16M)(23.67M)(73.94M)
Capital Expenditures(1.09M)(1.2M)(206K)(9.09M)(5.45M)
Acquisitions (Net)006.56M351K0
Purchases of Investments(32.46M)(33.5M)000
Sales of Investments16.4M19.7M28.25M00
Other Investing Activities00000
Investing Cash Flow(17.14M)(15M)34.61M(8.74M)(5.45M)
Debt Repayment00(27.46M)00
Common Stock Issued51.96M38.98M0124.44M(301K)
Common Stock Repurchased00(6.17M)00
Dividends Paid00000
Other Financing Activities939K235K231K3.99M(7.75M)
Financing Cash Flow52.9M39.22M(13.15M)168.43M(8.06M)
Effect of Forex Changes(3K)20K(53K)(21K)45K
Net Change in Cash(24.63M)(7.4M)(29.75M)135.99M(87.41M)
Free Cash Flow(61.47M)(32.83M)(51.37M)(32.77M)(79.4M)

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.